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1. Introduction 
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia and 
derangement in protein and fat metabolism [1]. The worldwide prevalence of diabetes was 
approximately 2.8% in 2000 and is estimated to grow to 4.4% by 2030. Approximately 40% of 
patients with type 1 diabetes and 5 - 15% of patients with type 2 diabetes eventually develop 
end stage renal disease (ESRD), although the incidence is substantially higher in certain 
ethnic groups [2, 3]. The main risk factors for the development of diabetes are ethnic 
variations, changes in the food habits, obesity and altered lifestyles. However in type 2 
diabetic patient additional factors, related or unrelated to diabetes plays an important role in 
causation of diabetic nephropathy such as hypertension, dyslipidemia, obesity and it has 
been named as metabolic syndrome [4]. There are mainly three types of diabetes which 
include Type 1 diabetes, Type 2 diabetes including a related condition called pre-diabetes 
and gestational diabetes. The occurrence of diabetic nephropathy varies with type of 
diabetes and highest risk indiviusuals are type 1 diabetics, but also type 2 diabetics have 
significant risk. The studies have shown that incidence of renal failure in type 1diabetes may 
be decreasing due to better preventive measures. However the incidence of renal 
complications in type 2 diabetes showed uprising [5-8] because type 2 diabetes accounts for 
at least 90% of all patients with diabetes. Thereby number of type 2 patients with 
nephropathy and ESRD exceeds those with type 1 diabetes overall.  
Diabetic nephropathy is one of the most serious complication of diabetes and the most 
common cause of end stage renal disease. Advanced diabetic nephropathy is also the 
leading cause of glomerulosclerosis and end-stage renal disease worldwide. 20% to 40% of 
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patients with diabetes ultimately develop nephropathy, although the reason why not all 
patients with diabetes develop this complication is unknown [9]. The combination of 
hypertension and diabetes is an especially dangerous clinical situation; both are risk factors 
as singly or in combination for micro vascular and macro vascular complications of diabetes 
and for diabetes-related mortality. It’s unfortunate that most of diabetics at the time of 
diagnosis will have hypertension and studies have shown that 50% of patients with diabetes 
and hypertension results in a sevenfold increase in mortality [10]. Concomitant nephropathy 
in patients with diabetes and hypertension results in a 37-fold increase in mortality.  
The main treatment dialysis and renal transplantation are costly [11, 12] and most of the 
poor patients cannot afford the same. Patients with type 2 diabetes undergoing maintenance 
dialysis require significantly higher financial resources than those suffering from 
nondiabetic end-stage renal diseases. Furthermore, this group of patients has a very poor 
prognosis on maintenance dialysis owing to extremely high mortality due to various 
cardiovascular events [13]. 
Is the diabetic nephropathy preventable, the answer is yes as diabetic nephropathy 
progresses from subclinical disease, through the earliest clinically detectable stage 
characterized by microalbuminuria i.e., urinary albumin 30 to 300mg/day to overt 
nephropathy with macroalbuminuria [14-16].The combination of strict glycemic control and 
various biochemical parameters in the form of microalbuminuria, glycated hemoglobin have 
decreased the occurrence of nephropathy. 
Various sensitive tests are available to identify patients with renal involvement early in the 
clinical course and clinicians should have the knowledge about diabetic nephropathy in the 
form of its onset, prevention, progression, and treatment in their patients.  
Detection of microalbuminuria identifies not only individuals who are at risk of developing 
renal diseases [(17, 18] but also cardiovascular events and death [19] in these patients. Up to 
30% of people with newly diagnosed type 2 diabetes will already have abnormally high 
urine albumin levels I.e. macroalbuminuria which indicates that many may have overt 
diabetic nephropathy at the time of diagnosis.  
Renal disease is strongly linked to heart disease and the presence of microalbuminuria is a 
predictor of worse outcomes for both in renal and cardiac patients. Microalbuminuria does 
not directly cause cardiovascular events; it serves as a marker for identifying those who may 
be at increased risk. Microalbuminuria is caused by glomerular capillary injury and so may 
be a marker for diffuse endothelial dysfunction. According to Steno hypothesis, albuminuria 
might reflect a general vascular dysfunction and leakage of albumin and other plasma 
macromolecules such as low density lipoproteins into the vessel wall that may lead to 
inflammatory responses and in turn start the atherosclerotic process [20, 21]. 
Recently, it has been suggested that microalbuminuria may be a risk factor for the 
development of cardiovascular disease in non-diabetics and may therefore have a role in 
screening programs [22]. 
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Early detection of nephropathy through screening of diabetic patients allows early 
intervention and better control of progression of nephropathy and cardiovascular events 
and mortality. 
1.1. Socio-economic burden of diabetes in India 
Type 2 diabetes is the commonest form of diabetes constituting 90% of the diabetic 
population in any country and prevalence of diabetes is estimated to increase from 4% in 
1995 to 5.4% by the year 2025 (23). The countries with the largest number of diabetic subjects 
are India, China and U.S. and in the former two countries diabetes occurs mostly in the age 
range of 45-64yrs, in contrast with an age of >65 in the developed countries. Epidemiological 
studies conducted in India showed that not only was the prevalence high in urban India but 
it was also increasing [24-26]. This is mainly attributed to life style changes and genetic 
predisposition in Indian population.  
The period between1989-95 showed a 40% rise in the prevalence and subsequently a 
further increase of 16.4% was seen in the next 5 years. A national survey of diabetes 
conducted in six major cities in India in the year 2000 showed that the prevalence of 
diabetes in urban adults was 12.1%. The prevalence of impaired glucose tolerance (IGT) 
was also high (14.0%). A younger age at onset of diabetes had been noted in Asian Indians 
in several studies [26, 27]. 
In the national study, onset of diabetes occurred before the age of 50 years in 54.1% of cases, 
implying that these subjects developed diabetes in the most productive years of their life 
and had a greater chance of developing the chronic complications of diabetes. The recent 
studies found that the occurrence of diabetic nephropathy with respect to age is been 
decreasing and most of people affected in early ages.  
Table 1 shows the prevalence of the vascular complications observed in a study by the 
Diabetes Research Centre [28].  
 
Microvascular Macrovascular 
Retinopathy                           23.7 
Background                           20.0 
Proliferative                           3.7 
Nephropathy                         5.5 
Polyneuropathy                    27.5 
Cardiovascular disease              11.4 
Peripheral vascular disease       4.0 
Cerebrovascular accidents         0.9 
Hypertension                               38.0 
Table 1. Prevalence () of vascular complications in type 2 diabetes 
Prevalence of retinopathy is high among the Indian type 2 diabetic subjects. Another study 
done in 1996 in South India showed a prevalence of 34.1% of retinopathy [29]. The 
prevalence of nephropathy in India was less (8.9% in Vellore) [30]. 5.5% in Chennai [28] 
when compared with the prevalence of 22.3% in Asian Indians in the UK in the study by 
Samanta et al in 1991[31]. 
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1.2. The main health problems related to diabetes are 
Diabetes can have a significant impact on quality of life by increasing risk for a variety of 
complications mainly long standing. These include: 
Chronic complications
Blindness(Mainly cataract and retinopathy) 
Renal Disease 
Hypertension 
Cardiac Disease and Stroke 
Amputations 
Nervous System Disease 
Pregnancy complications 
Table 2. Main chronic complications in diabetes 
2. Diabetic nephropathy 
The abnormal glycemic status of diabetes is closely related to the development of micro-
vascular complications. However, in humans the evidence of a straightforward causal 
relationship between hyperglycemia and renal disease is less compelling than in animal 
models. The development of diabetic nephropathy is characterized by a progressive increase 
in the excretion of albumin, continued increase in blood pressure and decline in glomerular 
function which later leads to end stage renal failure. The patients with diabetes are more 
prone for this condition due to associated factors like hyperlipidemia and hypertension. The 
mortality and morbidity is high and it’s mainly due to a cardiovascular event [32, 33]. 
There are various factors which lead to diabetic nephropathy like biochemical, hormonal, 
immunological and rheological. 
 Biochemical factors include long standing hyperglycemia and glycosylation process 
[34]. 
 Studies have shown that growth hormone promotes basement membrane thickening in 
diabetes [35]. 
 Both exogenous and endogenous insulin autoantibodies, IAA contributed in basement 
membrane thickening [36]. 
 The red blood cell deformity due to glycosylation and fibrin deposition results in 
altered permeability and hypercoagulability in diabetic patients [37]. 
2.1. Genetic and ethnic role 
Although we know that all patients with diabetes will not develop ESRD this is due to the 
good glycemic and blood pressure control. In addition to the risks of poor glycemic control 
and hypertension, a subset of patients may be at greater risk for nephropathy based on 
inherited factors. Familial clustering of patients with nephropathy may result from similarly 
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poor glycemic or blood pressure control or may have additional independent genetic basis 
[38, 39]. 
Diabetic siblings of patients with diabetes and renal disease are five times more likely to 
develop nephropathy than diabetic siblings of diabetic patients without renal disease. Even 
this has been proved by histo-pathological studies in twins with type 1 diabetics [40, 41]. 
Genetic factors may play an important role in diabetic nephropathy and/or may be clustered 
with genes influencing other cardiovascular diseases. There is ongoing research in 
identifying genetic loci for diabetic nephropathy susceptibility through genomic screening 
and candidate gene approaches [42-44]. A recent genome scan for diabetic nephropathy in 
African Americans identified susceptibility loci on chromosomes 3q, 7p and 18q [45] and in 
Pima Indians it has been identified on chromosome 7 [46].  
Diabetic nephropathy and hypertension are multifactorial disorders resulting from  
both environmental and genetic factors, which make it complex and difficult to identify  
at the genetic level what confers susceptibility to diabetic kidney disease. Gene 
polymorphism play’s an important role for example in renin–angiotensin system, nitric 
oxide (NO), aldose reductase, glucose transporter 1 (GLUT-1), and lipoproteins which are 
potentially involved in the genetic predisposition to hypertension, vascular reactivity, and 
insulin resistance [47].  
A recent study has shown that the strong association between a polymorphism in the 5′-end 
of the aldose reductase gene and the development of diabetic nephropathy in type 1 diabetic 
patients [47]. 
ESRD is known to be more prevalent in certain ethnic groups—Native Americans, Mexican 
Americans, and African Americans—than in Caucasian Americans. Certainly, there is 
reason for special vigilance for early signs of nephropathy in these high-risk populations, 
whose members presumably have a genetic predisposition to nephropathy.  
The factors which contribute for the development of diabetic nephropathy are shown in 
Table 3. 
 
Metabolic factors  Advanced glycation end products (AGEs) 
 Aldose reductase (AR)/ Polyol pathway 
Hemodynamic factors  Angiotensin 2 / renin – angiotensin system (RAS) 
 Endothelin 
 Nitric oxide 
Intracellular factors  Diacyglycerol (DAG) – protein kinase C (PKC) pathway 
Growth factors and 
cytokines 
 Transforming growth factor β (TGF- β) 
 Growth hormone (GH) and insulin –like growth  
 Factors (IGFs) 
 Vascular endothelial growth factor (VEGF) 
 Platelet-derived growth factor (PDGF) 
Table 3. Factors involved in development of diabetic nephropathy 
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2.2. Natural history of diabetic nephropathy (Table 3) and renal changes in 
diabetic nephropathy 
Diabetic nephropathy is a spectrum of progressive renal lesions secondary to diabetes 
mellitus ranging from renal hyper-filtration to end stage renal disease. The earliest clinical 
evidence of nephropathy is the presence of microalbuminuria. It occurs in 30% of type 1 
diabetics 5 to 15 years after diagnosis but may be present at diagnosis in type 2 diabetics as 
the time of onset of type 2 diabetes is often unknown. The microalbuminuria progresses to 
overt proteinuria over the next 7 to 10 years. Once overt proteinuria develops, renal function 
progressively declines and end stage renal disease is reached after about 10 years. 
 
Stage 1  Glomerular hypertension and hyper filtration
 Normoalbuminuria: urinary albumin excretion rate (AER) <20 µg/min 
 Raised GFR, normal serum creatinine
Stage 2  “Silent phase” (structural changes on biopsy but no clinical 
manifestations) 
 Normoalbuminuria
Stage 3  Microalbuminuria: AER 20 – 200µg/min
 Normal serum creatinine 
 Increased blood pressure
Stage 4  Overt “dipstick positive” proteinuria (macroalbuminuria) : AER > 
200µg/min 
 Hypertension 
 Serum creatinine may be normal Increase in serum creatinine with 
progression of nephropathy
Stage 5  End stage renal failure
 Requiring dialysis or transplant to maintain life
Adapted from SIGN Guidelines (48) 
Table 4. Evolution of diabetic renal disease 
Renal changes are characterized by specific renal morphological and functional alterations 
which include: 
 Features of early diabetic changes in the form of glomerular hyper filtration, glomerular 
and renal hypertrophy, increased urinary albumin excretion (UAER). 
 Increased basement membrane thickness (BMT) and mesangial expansion with the 
accumulation of extracellular matrix (ECM) proteins such as collagen, fibronectin and 
laminin.  
 Advanced diabetic nephropathy is characterized by proteinuria, a decline in renal 
function, decreasing creatinine clearance, glomerulosclerosis and interstitial fibrosis.  
3. Pathophysiology of microalbuminuria 
Normal human urine contains only very small quantities of albumin, less than 30 mg of 
albumin being excreted by healthy adults in 24 hours. The appearance of large amounts of 
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albumin in the urine is a cardinal sign of renal damage, especially glomerular disease, and is 
not detectable by screening techniques using urinary dipsticks.  
Various studies have shown different factors play a role in microalbuminuria. The two 
important factors plays a role in urinary albumin excretion are trans glomerular passage of 
albumin and tubular reabsorption. The glomerular and tubular proteinuria can be 
distinguished by simultaneously measuring the urinary β2-microglobulin and albumin [49, 50].  
Rodicio et.al., in their article has put forward the causes of microalbuminuria in 
hypertension which is invariably associated with diabetes as follows: -  
 Can be a consequence of an augmented intraglomerular capillary pressure.  
 Reflects the existence of intrinsic glomerular damage leading to changes in the 
glomerular barrier filtration. 
 May be the result of a tubular dysfunction in normal reabsorption of filtered albumin.  
 It may be the renal manifestation of a generalized, genetically conditioned vascular 
endothelial dysfunction which may therefore link urinary albumin excretion and 
elevated  risk of cardiovascular diseases [51].  
3.1. Structural abnormalities seen during increased excretion of albumin 
There is a general belief that increased urine albumin excretion in diabetic nephropathy is 
mostly glomerular in origin. For albumin to appear in the urine it must cross the glomerular 
filtration barrier, which consists of fenestrated glomerular endothelial cells, the glomerular 
basement membrane, and glomerular epithelial cell or podocyte. 
It has been seen that increased intraglomerular pressure, loss of negatively charged 
glycosaminoglycan’s in the basement membrane and, later, increased basement membrane 
pore size, all contribute to the albuminuria. The earliest morphological change of diabetic 
nephropathy is expansion of the mesangial area [52] and is caused by an increase in 
extracellular matrix deposition and mesangial cell hypertrophy. After a short period of 
proliferation, mesangial cells exposed to hyperglycemia become arrested in the G1-phase of 
the cell cycle and is mediated by p27 Kip1, an inhibitor of cyclin-dependent kinases [53, 54].  
Hyperglycemia activates the mitogen-activated protein kinases (MAPKs) which lead to a 
post-transcriptional increase in p27 Kip1 expression [55].  
In addition, ANG II further enhances p27 Kip1 induction and blockade of ANG II attenuates 
high glucose mediated mesangial cell hypertrophy [54]. Thickening of the GBM is 
progressive over years; both increased extracellular matrix synthesis and impaired removal 
contribute to GBM thickening.  
There is a decrease in the expression of heparin sulphate and the extent of sulphation 
followed by increase in collagen type IV deposition. The type of collagen expressed in GBM 
mainly contains α 3, α 4, and α 5 chains and mesangial matrix has α 1 and α 2 of type IV 
collagen and increased expression is seen in diabetic populations [56, 57]. 
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The recent evidence shows that an alteration in structure and function of podocytes occurs 
early in diabetic nephropathy. The podocytes which are adhering to GBM through integrin’s 
are altered due to hyperglycemia. 
In addition, renal biopsies from Pima Indians showed a broadening in podocyte foot 
processes and a concomitant reduction in the number of podocytes per glomerulus [58] in 
type 2 diabetic patients. 
The structural abnormalities seen are: 
 
Mesangial expansion Fibrin cap lesion
Glomerulosclerosis (diffuse, nodular)  
Basement membrane thickening (glomerular 
and tubular) 
Endothelial foam cells 
Arteriosclerosis Tubular atrophy
Capsular drop lesion Interstitial fibrosis
Interstitial inflammation Podocyte abnormalities
Table 5. Main structural abnormalities in diabetic nephropathy 
3.2. Glomerular and tubular mechanisms 
The alterations in glomerular function and tubular reabsorption play an important role in 
microalbuminuria. The glomeruli receive 25% of cardiac output per day. Of the 70kg of 
albumin that passes through the kidneys every 24hr, less than 0.01% reaches the glomerular 
ultra filtrate and hence enters the renal tubules [59, 60, and 61]. Almost all filtered albumin 
is reabsorbed by proximal tubule via a high affinity, low capacity endocytic mechanism with 
only 10-30mg/24hour appearing in the urine [62]. 
The passage of albumin through glomeruli depends on two main factors, charge and size. 
The negative charge on the glomerular membrane repels the anionic proteins thereby 
preventing the passage of albumin molecules through glomeruli normally. The loss of 
glomerular charge selectivity has been found in both diabetics and non-diabetic population 
with microalbuminuria [63, 64]. 
Established microscopic abnormalities include thickening of the glomerular basement 
membrane, accumulation of mesangial matrix, and increase in the numbers of mesangial 
cells with disease progression there is a close relationship between mesangial expansion and 
declining glomerular filtration [65].  
Mesangial expansion also correlates inversely with capillary filtration surface area, which 
itself correlates with glomerular filtration rate. Changes in the tubulointerstitium, including 
thickening of tubular basement membrane, tubular atrophy, interstitial fibrosis and 
arteriosclerosis, have been well described. Interstitial enlargement correlates with 
glomerular filtration, albuminuria, and mesangial expansion. It has been suggested that the 
accumulation of protein in the cytoplasm of proximal tubular cells causes an inflammatory 
reaction which leads to tubulointerstitial lesions [65]. Similarly, rise in blood pressure plays 
an important role by altering the fraction of plasma filtered by the glomerulus. 
Bio-Chemical Aspects, Pathophysiology of  
Microalbuminuria and Glycated Hemoglobin in Type 2 Diabetes Mellitus 27 
3.3. Changes in endothelial function 
Increased systemic capillary permeability has also been linked with microalbuminuria in 
healthy populations and recent study shows that endothelial dysfunction leads to impaired 
insulin action as well as to capillary leakage of albumin [67, 68]. 
Therefore, microalbuminuria may be a marker of generalized vascular disease, as  
the formation of atherosclerotic thrombi is related to endothelial dysfunction in arteries. 
Thus in addition to being an early marker of incipient diabetic nephropathy, urinary 
albumin excretion may represent common pathways for the development of both large and 
small vessel disease making microalbuminuria as a possible marker for cardiovascular 
diseases. 
3.4. Cellular and molecular mechanisms 
Abnormalities of many cellular processes have been described in the kidney cells  
of experimental and/or human diabetes. Most work so far has been focused on the 
glomerular endothelial and mesangial cells. Direct effects of hyperglycemia per se (glucose 
toxicity), glycation, formation of advanced glycation products, increased flux through the 
polyol and hexosamine pathways have all been implicated in the pathogenesis of diabetic 
nephropathy.  
Recently it has been suggested that the central abnormality linking all of these pathways is 
oxidative stress, a defect in the mitochondrial electron transport chain resulting in over-
production of reactive oxygen molecules which stimulate each of the above pathways [69]. 
Increased activity of a large number of growth factors has been demonstrated in diabetes 
[70].  
 Transforming growth factor ß-1 and connective tissue growth factor: May be involved 
in the fibrotic changes seen in mesangium and interstitium.  
 Growth hormone and insulin like growth factor-1 (IGF-1) appear to be associated with 
the glomerular hyper filtration and hypertrophy.  
 Vascular endothelial growth factor (Synthesized by the podocyte): Plays a major role in 
maintaining the fenestrae in glomerular endothelial cells, has pressor effects leading to 
constriction of the efferent glomerular arterioles.  
 Glucose itself also stimulates some signaling molecules, leading to the increased intra 
glomerular pressure. Several isoforms of protein kinase C, diacyl glycerol, mitogenic 
kinases, and transcription factors are all activated in diabetic nephropathy. 
3.5. Hemodynamic abnormalities 
The glomerular hemodynamic changes in the form of hyper filtration and hyper perfusion 
results in decreased resistance in both afferent and efferent arterioles of the glomerulus. 
Many diverse factors including prostanoids, nitrogen oxide (NO), atrial natriuretic factor, 
growth hormone, glucagon, insulin, angiotensin II (ANG II), and others have been 
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implicated as agents causing hyperperfusion and hyper filtration [71].Hyperglycemia itself 
stimulates the synthesis of angiotensin II, which leads to various hemodynamic changes in 
the form of trophic, inflammatory and profibrogenic effects. 
The vascular endothelial growth factors (VEGFs), and cytokines, such as transforming 
growth factor β (TGF-β), may mediate hyper filtration by dilatation of the afferent vessels by 
inhibiting calcium transients [72]. Furthermore, TGF- β increases NO production in early 
diabetes, probably by up-regulation of endothelial NO synthase (eNOS) mRNA expression 
and by enhancing arginine resynthesis [72]. Thus, TGF- β could clearly play a role in 
diabetic vascular dysfunction [74]. 
The studies have shown that shear stress and mechanical strain causes hemodynamic 
alterations by inducing the autocrine and/or paracrine release of cytokines and growth 
factors. 
The factors contributed are: 
 Renin-angiotensin system 
 Vasoactive hormones such as nitric oxide, prostacyclin, Endothelin -1,Urotensin 
4. Role of glycated hemoglobin in diabetes 
Glycated hemoglobin (HbA1c), a marker of average glycaemia, is a predictor of micro 
vascular complications in diabetic individuals. However, it is not yet clear whether the 
HbA1c is an indicator of the risk of the macro vascular complications associated with 
diabetes mellitus. 
HbA1c is the product of non-enzymatic reaction between glucose and free amino groups of 
hemoglobin. This reaction, called glycosylation, involves lots of other proteins, too and it is 
the principal mechanism through which glucotoxicity occurs. Other mechanism involved s 
is: oxidative stress, activation of the polyols pathway, activation of protein kinase-C, 
endothelial damage, hemodynamic and coagulative changes [75]. 
HbA1c reflects average plasma glucose over the previous 8 to 12 weeks as the life span of 
RBC’s is 80-120days [76]. It can be performed at any time of the day and does not require 
any special preparation such as fasting. These properties have made it the preferred test for 
assessing glycemic control in diabetics. More recently, there has been substantial interest in 
using it as a diagnostic test for diabetes and as a screening test for persons at high risk of 
diabetes [77]. The use of HbA1c can avoid the problem of day-to-day variability of glucose 
values, and importantly it avoids the need for the person to fast and to have preceding 
dietary preparations. These advantages have implications for early identification and 
treatment which have been strongly advocated in recent years. 
However, HbA1c may be affected by a variety of genetic, hematologic and illness-related 
factors [78]. The most common important factors worldwide affecting HbA1c levels are 
hemoglobinopathies (depending on the assay method employed), certain anemia’s, and 
disorders associated with accelerated red cell turnover such as malaria [79]. 
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Long term prospective studies are required in all major ethnic groups to establish more 
precisely the glucose and HbA1c levels predictive of micro vascular and macro vascular 
complications. A working group should be established to examine all aspects of HbA1c and 
glucose measurement methodology. 
The diagnosis of diabetes in an asymptomatic person should not be made on the basis of a 
single abnormal plasma glucose or HbA1c value. At least one additional HbA1c or plasma 
glucose test result with a value in the diabetic range is required, fasting, a random (casual) 
sample, or the oral glucose tolerance test (OGTT) report. 
The main long term vascular complications are coronary artery disease, stroke, renal failure 
etc. The measurement of glycosylated hemoglobin (GHb) is one of the well-established 
means of monitoring glycemic control in patients with diabetes mellitus [80]. In 1968 
Bookchin and Gallop subsequently reported that the largest of these minor fractions, 
designated HbA1c, had a hexose moiety linked to the N-terminus of the β-globin chain 
[81].The functions of many proteins depend upon post translational modification, 
hemoglobin is one such protein [82]. Hemoglobin (Hb) is composed of four globin chains 
and adult hemoglobin (HbA) is the most abundant form in most adults and consists of two 
α and two β chains. Fetal hemoglobin (HbF), which is predominantly present at birth, 
consists of two α and two γ chains. HbF is a minor form in normal adults. HbA2 is minor Hb 
after birth and consists of two α and two δ chains. The most common Hb variants 
worldwide in descending order of prevalence are HbS, HbE, HbC and HbD. All of these 
hemoglobin’s have single amino acid substitutions in the β chain. Normal adult hemoglobin 
consists primarily of hemoglobin’s A (90-95%), A2 (2-3%), F (0.5%), Ala (1.6%), Alb (0.8%), 
and A1c (3-6%). Glycosylated hemoglobin’s (GHb) are the minor hemoglobin molecules 
separable by chromatographic techniques into three major components: Ala, Alb, and A1c. 
Hemoglobin Al refers to a combination of these three components [83]. 
Important perspective studies on chronic complications of Diabetes mellitus allowed us to 
establish with absolute certainty the role of glycosylated hemoglobin (HbA1c) as a marker of 
evaluation of long term glycemic control in diabetic patients and the strict relationship 
between the risk for chronic complications and HbA1c levels. Diabetes Control and 
Complication Trial (DCCT), a great extent study, has demonstrated that the 10% stable 
reduction in HbA1c determines a 35% risk reduction for retinopathy, a 25- 44% risk reduction 
for nephropathy and a 30% risk reduction for neuropathy [84]. 
4.1. Glycosylation process 
Glycosylation is a non-enzymatic reaction between free aldehyde group of glucose and free 
amino groups of proteins. A labile aldiminic adduct (Schiff base) forms at first, then, 
through a molecular rearrangement, a stable ketoaminic product slowly accumulates.  
In the hemoglobin, the preferential glycosylation site is the amino-terminal valine of the β 
chain of the globin (about 60% of glycosylated globin). Other sites are: lysin 66 and 17 of the 
β chain, valine 1 of the α chain. The term HbA1c refers to the hemoglobin fraction of the 
glucose bound stably (ketoamine) to beta terminal of valines. 
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4.2. Other proteins which undergo glycosylation 
Albumin, α2 macroglobulin, antithrombin III, fibrinogen, ferritin, HDL, LDL, transferrin; all 
of them are short half-life proteins. The glycosylation process of short half-life proteins stops 
at the formation of the stable ketoamine adduct. 
4.3. Advanced Glycosylation End products (AGE) 
The long half-life proteins such as actin, collagen, fibronectin, myelin, nucleoproteins, spectrin, 
and tubulin can also be glycosylated. These long half-life proteins (myelin and collagen) 
undergo a complex and irreversible rearrangement process, with the formation of Advanced 
Glycosylation End products (AGE). AGE form a family with many compounds, only partially 
identified; they accumulate in the structural proteins modifying the function of them. They 
bind to specific macrophage receptors inducing a release of hydrolytic enzymes, cytokines and 
growth factors able to promote the synthesis of fundamental substance and, acting at 
intracellular level, to determine a damage of the nucleic acids [85, 86].  
Three mechanisms have been postulated that explain how hyperglycemia causes tissue 
damage: nonenzymatic glycosylation that generates advanced glycosylation end products, 
activation of PKC, and acceleration of the aldose reductase pathway. Oxidative stress seems 
to be a common to all three pathways. 
5. Note on laboratory aspects 
5.1. Microalbuminuria estimation 
5.1.1. Sample handling  
The collection of sample is very important when you are measuring MA. As many factors 
will alter the value and errors may occur due to improper aseptic precautions, improper 
storage and handling. After the collection it is preferable to measure on the same day and if 
urine albumin is not estimated immediately then urine can be stored at 4°C. Alternatively, 
2ml of 50 g /L sodium azide can be added per 500ml of urine. Specimens are stable for at 
least 2 weeks at 4°C and 5 months at -70°C. Freezing samples may decrease albumin but 
mixing immediately before assay eliminates this effect [87]. 
Albumin excretion varies with physiological factors like exercise posture, diuresis. Thus 
samples should not be collected after exercise, in the presence of urinary tract infection, 
during acute illness, immediately after surgery or after an acute fluid overload.  
The following are considered acceptable [88]:  
 24 hour collection is preferred by some centers but this is cumbersome and errors may 
occur due to improper sample collection and transport. 
 Overnight (8 - 12 hour) urine sample collection  
 Short term urine collection i.e. 1-2 hour collection (in laboratory or clinic)  
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 Early morning mid-stream urine sample is usually rather concentrated and using this 
sample has good correlation between the excretion rate and concentration of albumin. 
Many conditions can give a false positive value. Some of these common conditions are 
shown in table 6: 
 
 Acute hyperglycemia  Urinary tract infection 
 Hypertension- Independently causes 
microalbuminuria 
 Cardiovascular diseases- Independent 
of diabetes 
 Heavy exercise- Due to increased protein 
catabolism and altered renal circulation 
 Febrile condition and Stress 
 Contamination with seminal or menstrual fluid- Which has more amount of albumin 
Table 6. Various factors affecting microalbumin estimation 
 
Semi quantitative methods
 Principle 
Micral microalbumin urine test 
strip  
Immunochemical strip test is specific for albumin. 
Albumin in the sample is bound by soluble conjugate of 
antibodies and the β-galactosidase enzyme marker. 
Conjugate-albumin complexes are separated and the β -
galactosidase enzyme reacts with a substrate to produce 
a red dye. The intensity of the color produced is 
proportional to the albumin concentration in the urine. 
Clinitec Microalbumin  The test strip is based on dye binding by albumin 
method. It uses the high affinity dye bis (3,3’-diiodo- 4, 
4’-dih ydroxy-5, 5’-di nitrophenyl)-3,4,5,6- 
tetrabromosulfonephthalein. At a constant pH, the strip 
turns blue in the presence of albumin, and color is 
directly related to albumin concentration in the urine 
sample. 
Quantitative 
Immunoturbidimetry In this process turbidity is produced by an immune 
complex reaction. This causes a reduction in the 
intensity of light as it passes through the solution. 
Turbidimetry is the measurement of this loss in 
intensity because of scattering, absorption or reflection 
of the incident light in the angle/direction of the incident 
light.  
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Most colorimeters and spectrophotometers can measure 
turbidity with good precision and accuracy. This is the 
most widely used test as it can be done on most semi 
auto chemistry analyzers. It can even be done on 
automated chemistry analyzers.  
Nephelometry This assay is also based on scatter detection but unlike 
turbidimetry it measures scattered light at 90° to the 
incident light. The instrument is called a nephelometer. 
It is more sensitive than turbidimetry. 
Radio immunoassay (RIA)  This assay procedure involves competitive binding 
between radio labelled and unlabelled molecules of 
antigen to high affinity, specific antibody. The amount 
of unlabelled antigen present in the specimen is 
measured by its competitive effect on the labelled 
antigen for limited antibody sites. It involves the use of 
radio isotopes like tritium (3H), 131I or 125I as labels. It has 
high sensitivity and specificity. The sample values are 
determined by comparison with a calibration curve. The 
advantages are sensitivity and precision, whereas the 
disadvantage is short shelf life and radioactivity of the 
reagents. 
Chemiluminescent immunoassay 
(CLIA)  
Chemiluminescence is a chemical reaction that emits 
energy in the form of light. When used with 
immunoassay technology, the light produced by the 
reaction indicates the amount of analyte in a sample. 
This again is of two types: 
Luminescent Immunoassay (LIA): Here the labelled and 
unlabelled antigen competes for the limited binding 
sites on the labelled antibody. An inverse relationship 
exists between concentration of labelled antibody bound 
to the antigen and the unlabelled antigen. 
Immuno Chemiluminometric assay (ICMA): This is a 
sandwich assay in which unlabelled antigen is 
sandwiched between antibody bound to paramagnetic 
particles and antibody labelled Acridinium ester (AE). A 
direct relationship exists between the concentration of 
antigen in the patient sample and the amount of light 
emitted during oxidation of the AE.  
Note: Advantages of both RIA and CLIA are highly sensitivity, specificity and reproducible. 
Disadvantages are unavailability, cost factor; proper infrastructure needed, radioactive hazards,  
Government permission for use of radioactive materials is the limiting factors. 
Table 7. Methods of estimation [87, 88] 
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Marker Type 1 diabetes sample 
assayed  
Type 2 diabetes sample 
assayed 
Glomerular transferrin Urine Urine 
Fibronectin Plasma Urine 
Serum laminin P1 - Serum 
Urine laminin P1  Urine Urine 
Type 4 collagen - Serum and urine 
Heparan sulfate proteoglycan Urine - 
Tubular proteins beta-2 
microglobulin 
Urine Urine and blood 
Retinol-binding protein Urine and serum Urine 
Tamm-Horsfall protein Urine - 
Alpha1-microglobulin Urine Urine 
N-acetyl-beta-D-glucoseaminidase Urine and serum Urine and serum 
Cholinesterase - Urine 
Gamma-glutamyl transpeptidase - Urine 
Alanine aminopeptidase - Urine 
Tubular antigens,brush-border 
antigen 
- Urine 
Table 8. Newer markers of diabetic nephropathy [89]: 
6. Methods of estimation of glycated hemoglobin 
In the last 20 years improved techniques in laboratory and new electrophoretical, 
chromatographic and immunological methods available, gave us a greater reliability on 
results. However the use of different methods, the lack of a common calibration concerning the 
same method and the variability of instrumentation do not make reproducible results yet in 
different laboratories. For this reason studies and procedures of standardization are going on 
[89]. Methods of GHb assays have primarily evolved around three basic methodologies: 
1. Based on difference in ionic charge. 
2. Based on structural characteristics. 
3. Based on chemical reactivity. 
The main methods are, 
 Cation exchange chromatography 
 Affinity chromatography 
 High performance liquid chromatography 
 Isoelectric focusing 
 Radioimmunoassay 
 Spectrophotometric assay 
 Electrophoresis/Electroendosmosis 
 Electrospray mass spectrometry 
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6.1. Specimen collection 
Handling of specimens before the assay is important as short period of hyperglycemia 
before blood is taken, leads to an acute increase in the formation of aldimine which may 
increase the concentration of glycosylated hemoglobin by 10-20%--for example, from 9% to 
11% of total hemoglobin-thus reducing the reliability of the test as a measure of long term 
diabetic control.  
Blood samples should therefore be treated to remove the aldimine residues before the assay 
[91]. In measurement of HbA1c the prevalence of the most common hemoglobin variants 
(HbS, HbC, and HbD) depends on the genetic background of the population being analysed. 
There are many Hb variants that result in false low HbA1c level in diabetes. More than 700 
Hb variants are known and about half of these variants are clinically silent, their presence 
may falsely interfere with the measurement of HbA1c by HPLC. Hence, the identification of 
Hb variants is important to avoid inaccurate HbA1c results [92]. 
Recent reports have shown that the concentration of total glycosylated hemoglobin measured 
by commonly used methods may change significantly over a period of hours. This reflects the 
short term fluctuations in glucose concentration. It is now realized that these rapid changes 
will depend on the synthesis or dissociation of the labile fraction of HbA1c, which is not 
separable from the stable form of HbA1c, by most routine methods. In most cases, the labile 
fraction constitutes approximately 10% of the total glycosylated hemoglobin. This may 
increase to 25% when plasma glucose concentrations are high, as in poor glycemic control. 
These day to day variations in glycosylated hemoglobin concentration secondary to changes 
in serum glucose are negligible in stable diabetics, but are very wide in unstable diabetics 
and are almost entirely dependent on the prevailing plasma glucose concentration. Thus, 
during poor glycemic control there will be large swings in plasma glucose levels, a single 
HbA1c measurement may be misleading as an index of long term control. It would therefore 
make sense to measure the stable fraction of glycosylated hemoglobin. However, this is not 
routinely available because most laboratories measure total HbA1 or HbA1c, which includes 
both labile and stable components. Therefore, in unstable diabetics, HbAl measurements 
should be interpreted in relation to the simultaneous glucose concentration. To minimize the 
contribution of the labile fraction, glycosylated hemoglobin should be measured when the 
plasma glucose concentration is within or near the normal range. 
Physicians should be aware of the expected variation in HbA1c during conditions such as [93], 
 False increases in HbA1c levels may occur in the presence of HbF (Ex: Hereditary 
persistence of fetal Hb) and other negatively charged hemoglobin’s 
 HbA1c levels may also be increased in patients with renal insufficiency, caused by 
hemoglobin carbamylation resulting from condensation of urea with the same site to 
which glucose attaches. 
 Increased HbA1c occurs with advanced malignancy and iron deficiency anemia. 
 Increased levels can be seen in people with a longer red blood cell lifespan, such as with 
Vitamin B12 or folate deficiency.  
 Splenectomy can result in elevated levels of glycosylated hemoglobin 
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 False decreases may result when HbS (Ex: Sickle cell disease) or other positively 
charged variants are present 
 Hemolytic anemia and chronic blood loss result in decreased red cell life span and 
therefore lower glycosylated hemoglobin levels. 
6.2. Factors and clinical conditions affecting glycated hemoglobin levels are 
shown below [78] 
 
Increased glycated hemoglobin Decreased glycated hemoglobin 
 Iron and Vitamin B12 deficiency 
 Alcoholism  
 Chronic renal failure decreased 
intraerythrocyte pH 
 Increased erythrocyte life span: 
Splenectomy 
 Hyperbilirubinemias  
 Large doses of aspirin  
 Chronic opiate use 
 Administration of erythropoietin, Iron, 
Vitamin B12,  
 Reticulocytosis, Chronic liver disease. 
 Certain hemoglobinopathies, increased intra-
erythrocyte pH. 
 Decreased erythrocyte life span: 
hemoglobinopathies, splenomegaly, 
rheumatoid arthritis and drugs such as anti-
retrovirals, ribavirin, dapsone therapy. 
 Hypertriglyceridemia. 
Table 9.  
6.3. Advantages and disadvantages of various HbA1c assay methods 
 
Method Advantages Disadvantages
Ion Exchange 
Chromatography 
 Can inspect chromograms for Hb 
variants. 
 Measurements with great 
precision. 
 Variable interference from 
hemoglobinopathies, HbF 
and carbamylated Hb but 
the current ion exchange 
assays correct for HbF and 
carbamylated Hb does not 
interfere. 
Boronate Affinity 
 Minimal interference from 
hemoglobinopathies, HbF and 
carbamylated Hb. 
 Measures not only glycation 
of N-terminal valine on beta 
chain, but also beta chains 
glycated at other sites and 
glycated alpha chains. 
Immunoassays 
 Not affected by HbE, HbD or 
carbamylated Hb 
 Relatively easy to implement 
under many different formats. 
 Affected by 
hemoglobinopathies with 
altered amino acids on 
binding sites. 
Table 10.  
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7. Diagnosis of diabetes, its complications and management 
Diabetes screening is recommended for: 
 Overweight children 
 Overweight adults (BMI greater than 30)  
 Adults over age 45  
 Family history of diabetes along associated risk factors such smoking, hypertension etc.  
The diagnosis of diabetes is mainly done by using Oral Glucose Tolerance Test (OGT) and 
the values are shown in Table: 
 
NEW CRITERIA FOR DIAGNOSING 
DIABETES IN ADULTS 
NORMAL PLASMA GLUCOSE VALUES FOR 
ADULTS 
One or more of the following must be 
present: 
1. Fasting plasma glucose level of > 126 
mg/dL on at least two separate occasions. 
 
2. Random plasma glucose level of > 200 
mg/dL with signs and symptoms of 
diabetes. 
 
3. Fasting plasma glucose level < 126 
mg/dL but 2 hour glucose concentration 
of > 200 mg/dL during a 75-gram oral 
glucose tolerance test. 
Fasting
 
 
 
After 75g 
oral glucose 
load 
 
Time Zero
 
 
 
30 min 
 
60 min 
 
90 min 
 
120 min 
< 115 mg/dL 
(6.4 mM) 
 
 
< 200 mg/dL 
(11.1 mM) 
< 200 mg/dL 
(11.1 mM) 
< 200 mg/dL 
(11.1 mM) 
< 140 mg/dL 
(7.8 mM) 
Table 11.  
7.1. Frequency of visits and laboratory testing 
The recommended frequency of follow-up is 3-6 months for patients with type 1 diabetes 
and for type 2 diabetes patients depending on the glycemic status. 
 
Every 3 - 6 months Yearly
 Glycosylated hemoglobin
 Electrolytes, BUN and creatinine 
 Physical examination including foot 
examination by filament testing (Carville 
approach) 
 TSH
 U/A or urine for microalbumin 
 Complete chemistry panel (lipids, 
 LFT, electrolytes, BUN & creatinine) 
 Ophthalmology examination 
 Podiatry and nutrition
Table 12.  
The frequency of laboratory assessment is subject to flexibility, based on clinical judgment, 
patients’ current control of diabetes, and past laboratory values. 
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Podiatry if any evidence of neuropathy or breakdown of skin integrity, and nutrition, if 
dietary non-compliance is suspected. 
7.2. Microalbumin testing 
Type 1: Annual screening for type 1 diabetes should begin at puberty and for those patients 
who have had the disease for 5 years. 
Type 2: Initial testing at diagnosis and thereafter annual screening needed. 
Note: Microalbuminuria is urinary albumin excretion between 30-300 mg per day without 
an alternative explanation (e.g. urinary tract infection, heart failure, exercise in past 48 hours 
and blood glucose > 200 mg/dL). If no protein is found in a urine analysis, then a 24 hour 
urine collection for microalbumin or a spot urine albumin-creatinine ratio may be used 
(abnormal if > 30 mg albumin/ g creatinine) for screening. 
7.3. Retinopathy screening 
Baseline Screening: 
 For patients with type 1 diabetes who are 13 years of age or older and who have had the 
disease for 5 years, a baseline screening examination is recommended, and yearly 
thereafter. 
 For patients with type 2 diabetes, a baseline screening examination is recommended at 
the time diagnosis and yearly thereafter. 
Diabetic retinopathy is the leading cause of legal blindness among Americans, aged 20-74. It 
is highly correlated with patient age and duration of diabetes. Visual loss secondary to 
diabetic retinopathy is largely preventable if screening is universal and appropriate 
treatment follows screening. 
7.4. Vaccines 
 Pneumovaz every five years. 
 Influenza vaccine annually. 
Regular physical activity: Helps in movement of blood glucose into tissues. 
7.5. ACE inhibitors 
Recommendations: 
 All patients who demonstrate microalbuminuria should be prescribed ACE inhibitors to 
slow the progression of nephropathy whether they are hypertensive or normotensive. 
 Patients with type 1 who are hypertensive and do not demonstrate microalbuminuria 
should be prescribed ACE inhibitors. Such patients usually develop microalbuminuria 
in concert with hypertension and are best served by controlling blood pressure initially 
with ACE inhibitors. 
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 ACE inhibitors should not be used in pregnant women due to the risk of fetal morbidity 
and mortality.  
NOTE: 
ACE inhibitors should be titrated as high as the patient tolerates without orthostatic 
symptoms, hyperkalemia and /or increasing renal insufficiency. 
7.6. Oral hypoglycemic drugs and/or insulin therapy needed 
Some of the drugs used are, 
  Sulphonylureas 
 
First generation Second generation
Tolbutamide Glipizide
Tolazamide Glyburide
Acetohexamide Glibenclamide
Chlorpropamide Glimepiride
Table 13.  
 Meglitinides:Repaglinide, Nateglinide etc 
  Biguanides: Metformin etc 
 Thiazolidinediones: Pioglitazone etc 
  Alpha-glucosidase: Acarbose, Miglitol etc 
7.7. Life style changes such as cessation of smoking is necessary. 
7.8. Health education programs should be started. 
7.9. Self-monitoring of plasma glucose using glucometer.  
7.10. Management of diabetic complications. 
8. Conclusion 
The most common chronic complication in diabetic patients is ESRD and several factors 
contribute to the development of renal damage such as genetic factors, hypertension and 
hyperglycemia. 
The suspected cases of diabetic nephropathy will also invariably have diabetic retinopathy 
and more predisposed for cardiovascular events and mortality. That’s why it’s very 
important to prevent the condition then providing treatment. This is possible, as the 
progression of diabetic nephropathy is slow and can be detected at an early stage. 
Microalbuminuria is an early indicator of diabetic nephropathy and urine examination for 
micro albumin is routinely done to detect and monitor the progression of nephropathy. As 
many factors can interfere with the estimation of micro albumin, it is very important that 
high standards are maintained while estimating the MA levels. Other than 
microalbuminuria various newer markers have come, which still have to be studied for their 
probable role in its prevention of diabetic nephropathy.  
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Since, early detection of microalbuminuria can help in early diagnosis of diabetic 
nephropathy, adequate care and precautions has to be taken while estimating it. 
9. Further research 
Further studies have to be conducted to find better markers for chronic complications. 
Regular health education programs has to be conducted at an regular intervals, so that 
patients lead a better life. 
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